Medtronic plc (MDT)
Health Care4 articles
Price chart
Medtronic plc (MDT) overview
Medtronic is one of the world’s largest medical-device makers. It is a member of the S&P 500 and is classified in the Health Care sector — pharmaceutical, biotech, device and managed-care companies.
Medtronic plc trades on the NYSE under the ticker symbol MDT. As of the most recent market data, the stock was priced around $83.20, down 0.43% on the session.
Over the past 52 weeks, MDT has traded between $73.31 and $106.33. Shares are valued at a trailing price-to-earnings (P/E) ratio of about 22.4, a common gauge of how richly the market prices the company's earnings. Medtronic plc also pays a dividend, currently yielding around 3.45%.
Key statistics
Informational only, not financial advice. Content is AI-generated and may contain errors. How this works.
Why investors watch MDT
As one of the larger companies in the Health Care sector, Medtronic plc is closely followed by investors and often moves with broader trends across pharmaceutical, biotech, device and managed-care companies. Traders watch MDT for earnings reports, analyst rating changes, and headlines that can shift sentiment — each of which is summarized on this page as it breaks.
Market Mood
Latest MDT news
Medtronic (MDT) Reports Highest Annual Revenue Growth in Decade
Medtronic (MDT) reported its highest annual revenue growth in a decade, signaling a potential recovery after years of profitability challenges. The company boasts a 49-year dividend growth streak and currently offers a dividend yield of 3.5%. Conversely, Realty Income (O), a REIT, has maintained a 5.2% dividend yield, increasing its dividend for 31 consecutive years, making it attractive amid market volatility. Investor interest in reliable dividend stocks remains strong as corrections loom in the broader market.
Read More: Medtronic (MDT) Reports Highest Annual Revenue Growth in Decade
Medtronic (MDT) Tariff Impact Reduces Estimates to $250 Million
Medtronic plc (MDT) CEO Geoffrey Martha announced on June 8 that the company expects a tariff impact of $250 million for fiscal 2027, down from a previous estimate of $300 million. This figure includes $75 million expected in the first quarter. The reduction is due to supply chain adjustments, although Martha indicated that future tariff threats could alter these forecasts. Medtronic allocates $5 billion to $6 billion annually for innovation and reported a 78% revenue increase in cardiac ablation amidst ongoing cost pressures.
Read More: Medtronic (MDT) Tariff Impact Reduces Estimates to $250 Million
Medtronic (MDT) Reports Strong Q4 with $36 Billion Revenue Growth
Medtronic (MDT) recorded fiscal 2026 revenue of $36.36 billion, an 8.43% increase year-over-year. The company raised its quarterly dividend to $0.72, yielding approximately 3.52%, marking 49 consecutive years of increases. Trading at 14 times forward earnings, MDT demonstrates defensive value due to its non-discretionary medical procedures and a beta of 0.597. Key risks include a $185 million tariff and 230-basis-point margin compression, but underlying demographics may support long-term growth.
Read More: Medtronic (MDT) Reports Strong Q4 with $36 Billion Revenue Growth
Medtronic (MDT) Gains FDA Approval for New Robotic Surgery Platform
Medtronic (MDT) received FDA approval for its Hugo robotic-assisted surgery platform in December 2025, allowing it to perform urologic procedures. The first successful use occurred at Cleveland Clinic shortly after. This market is projected to grow from $13.8 billion in 2022 to $63.7 billion by 2035, yet Medtronic faces significant competition from Intuitive Surgical, which dominates the market with over 11,395 da Vinci systems installed globally. With a recent application for broader procedure approvals, Medtronic aims to expand its market presence but may have an uphill battle against a well-entrenched competitor.
Read More: Medtronic (MDT) Gains FDA Approval for New Robotic Surgery PlatformMore Health Care stocks
Frequently asked questions
Is Medtronic plc in the S&P 500?
Yes. Medtronic plc (MDT) is a member of the S&P 500 index, classified in the Health Care sector.
What sector is MDT in?
Medtronic plc is classified in the Health Care sector of the S&P 500 — pharmaceutical, biotech, device and managed-care companies.
Where can I find the latest MDT news?
This page collects recent Medtronic plc (MDT) news and market analysis, each article summarized by AI and tagged with bullish, bearish, or neutral sentiment.
What is Medtronic plc's stock price?
As of the most recent market data, Medtronic plc (MDT) traded at approximately $83.20. Prices move throughout the trading day, so this reflects the latest available quote rather than a live price.
What is MDT's P/E ratio?
MDT trades at a trailing price-to-earnings ratio of about 22.4. The P/E ratio compares a company's share price to its earnings per share.